BioSpace News Archive

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the Company has regained the commercialization and distribution rights in Europe for LYMPHOSEEK® (technetium Tc99m tilmanocept) injection from Norgine B.V. (“Norgine”). Navidea and Norgine have decided, by mutual agre

Nuvo Pharmaceuticals Inc., a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three months ended March 31, 2020.

Fast Track Designation Granted for IPI-549 Plus Opdivo ® in Patients with Advanced Urothelial Cancer – – Infinity Voluntarily Pausing Enrollment on MARIO-275 to Evaluate the Risk/Benefit for Patients – – Completion of Enrollment for MARIO-275 and MARIO-3 Delayed with Outlook for Completion of Enrollment and Impact on Data Readouts to Be Updated by 2Q Earnings Webcast – – $20M Asset Backed Financing with BVF in January; Cash Runway into

MarzAA Phase 3 study first patient enrollment targeted before year end following FDA and EMA regulatory feedback DalcA Phase 2b study completed, final data to be presented in the second quarter SOUTH SAN FRANCISCO, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2020 and provided a corporate update. “Despite disruptions in clinical and preclinical research operati

Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that it has received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. As previously reported, Ritter Pharmaceuticals is holding a special meeting of stockholders this week on May 14, 2020, at whi

Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of an oral presentation at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting. The virtual presentation will take place on May 16, 2020 at 6:00pm ET. The abstract is currently available on the ASCRS

6th Annual SunTrust Robinson Humphrey Life Sciences Summit Virtual Series Fireside Chat at 2:30 p.m. ET on May 15 TH RBC Capital Markets 2020 Global Healthcare Conference presentation at 1:20 p.m. ET on May 20 TH PITTSBURGH, May 11, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare genetic diseases caused by mutant genes, announced to

Neurophth Therapeutics, Inc., a clinical-stage biotechnology company discovering and developing innovative therapies for ocular and other genetic disease, today announced that the results of two clinical studies utilizing NFS-01 (rAAV2-ND4) in the treatment of Leber’s Hereditary Optic Neuropathy (LHON) will be presented in M

- Reached Agreement to be Acquired by Alexion; Transaction Expected to Close in Third Quarter - - Andexxa®/Ondexxya® Global Net Product Revenues of $25.6 Million - [11-May-2020] SOUTH SAN FRANCISCO, Calif. , May 11, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today reported financial results for the three months ended March

- 19% year-over-year increase in royalty revenues for XIAFLEX® - Highly experienced biopharma executive, Joseph Truitt, named as Chief Executive Officer and Mike Sherman and Corey Fishman appointed to Board of Directors - Initiation of CCH studies for plantar fibromatosis and adhesive capsulitis in 2H20 [11-May-2020] WILIMINGTON, Del., May 11, 2020